Ert Batten Brineura denied for missing prior authorization by Cigna?

Cigna's specific coverage criteria for ert batten brineura are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Requires Prior Authorization for Brineura and How to Navigate It

Prior authorization (PA) for Brineura (cerliponase alfa) is standard across most commercial payers for ultra-rare biologics. Cigna uses the PA process to verify that the prescribing meets their coverage criteria before agreeing to pay. A "prior-auth-required" denial typically means authorization was not obtained before the drug was dispensed or administered, or an authorization request was submitted and denied. The two situations require different responses.

If authorization was not obtained in advance: request a retroactive review and document why the clinical situation made advance PA impractical (e.g., urgent initiation, administrative failure). If authorization was sought and denied on clinical grounds: the PA denial triggers full appeal rights.

## Federal Appeal Rights

A PA denial is a coverage determination subject to the full appeal process under ACA Section 2719 (for ACA-governed plans) and ERISA Section 503 (for employer self-funded plans). You have the right to internal appeal and then independent external review by an IRO. For a child with a rapidly progressive neurological disease, expedited review (which compresses timelines to as little as 72 hours) is appropriate and should be requested explicitly. The external-review window is generally within 4 months of the final internal denial.

## Appeal Process and Timeline

1. Obtain the PA denial rationale — Cigna must provide the specific clinical criteria not met. Request this in writing if not already provided. 2. Internal appeal — respond to each unmet criterion with chart documentation. Submit within the plan's deadline (typically 180 days). 3. Peer-to-peer review — request a peer-to-peer call between the treating neurologist and Cigna's medical reviewer. This step alone overturns many PA denials for rare diseases. 4. External review — if the internal appeal fails, request IRO review immediately.

## Documentation to Gather

• Confirmed CLN2 diagnosis: genetic sequencing and enzyme activity assay results.
• Clinical history and severity: longitudinal neurologist assessments documenting disease progression and current functional status.
• Prescriber PA letter: addressing each of Cigna's PA criteria explicitly, with reference to the FDA-approved prescribing label and the applicable specialist-society guidance on CLN2 management.
• No adequate alternative documentation: statement that no other approved disease-modifying therapy exists for CLN2 disease.
• Treating center information: confirmation of specialist oversight, if required by Cigna's PA criteria.

## Criteria-Mapping Structure

Pull Cigna's PA criteria for Brineura from the denial letter or Cigna's provider portal. Pull the FDA-approved indication language from the prescribing label. For each PA criterion, document the specific chart fact, lab result, or clinical note that satisfies it. Present this as a numbered checklist in the appeal letter — this format makes it easy for the reviewing clinician to confirm each item is met and difficult to justify a continued denial.